![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
ABT-450/ritonavir (ABT-450/r) Combined With Pegylated Interferon Alpha-2a/Ribavirin (P/R) After 3-Day Monotherapy in
HCV Genotype 1 (GT1)-Infected Treatment-Naïve Subjects: 12-Week Sustained Virologic Response (SVR12) and Safety Results
|
|
|
Reported by Jules Levin
EASL 2012 Apr 18-22 Barcelona Spain
Eric Lawitz1, Fred Poordad2, Edwin DeJesus3, Kris V Kowdley4, Isabelle Gaultier5, Daniel Cohen5, Wangang Xie5, Lois Larsen5, Tami Pilot-Matias5, Rajeev M Menon5, Thomas Podsadecki5, Barry Bernstein5
1Alamo Medical Research, San Antonio, Texas, United States; 2Cedars-Sinai Medical Center, Los Angeles, California, United States; 3Orlando Clinical Research Center, Orlando, Florida, United States; 4Digestive Disease Institute, Virginia Mason Medical Center, Seattle, Washington, United States; 5Abbott, Abbott Park, Illinois, United States
![EASL1.gif](../images/042712/042712-3/EASL1.gif)
![EASL2.gif](../images/042712/042712-3/EASL2.gif)
![EASL3.gif](../images/042712/042712-3/EASL3.gif)
![EASL4.gif](../images/042712/042712-3/EASL4.gif)
![EASL5.gif](../images/042712/042712-3/EASL5.gif)
![EASL6.gif](../images/042712/042712-3/EASL6.gif)
![EASL7.gif](../images/042712/042712-3/EASL7.gif)
![EASL8.gif](../images/042712/042712-3/EASL8.gif)
![EASL9.gif](../images/042712/042712-3/EASL9.gif)
![EASL10.gif](../images/042712/042712-3/EASL10.gif)
![EASL11.gif](../images/042712/042712-3/EASL11.gif)
![EASL12.gif](../images/042712/042712-3/EASL12.gif)
![EASL13.gif](../images/042712/042712-3/EASL13.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|